Johnson & Johnson Ends Partnership With Bavarian Nordic on Hepatitis B and HPV Vaccines
On May 9, Johnson & Johnson announced that it had terminated its partnership and licensing agreement with Bavarian Nordic. The main content of the agreement is to use Bavarian Nordic's MVA-BN technology to develop potential vaccines against hepatitis B virus and human papilloma virus. Currently, J&J has not used the technology to develop a hepatitis B vaccine.
For hepatitis B, Johnson & Johnson will continue to prioritize the use of its technology platform to develop related therapeutic drugs. Because hepatitis B remains a serious health problem, about 296 million people worldwide are affected by the disease, and nearly 900,000 people die from it every year.
For human papillomavirus, J&J does not intend to focus its research on its therapeutic vaccine, as preventive vaccines are already widely used.
However, J&J's collaboration with the company on HIV and Ebola is still ongoing.
You May Interested In
2026-10-02
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
A share 'domestic nine-price HPV vaccine first share' IPO today, how will set off the phenomenon of the new changes in the market?
-
8 billion, the 'secret' layout outside the vaccine disc, and the distribution of dual antibody, CGT, CXO
-
GlaxoSmithKline HPV Vaccine Two-dose Schedule Approved in China
-
Wantai Bio's Bivalent HPV Vaccine Receives Marketing Approval in Morocco
-
China’s Agrochemical Role Expands as Global Supply Risks Intensify
-
Lilly’s U.S. API Investment Highlights a New Phase of Pharma Supply Localization
-
Pregabalin vs Gabapentin: Differences, Uses, and Side Effects
-
China’s Agrochemical Role Expands as Global Supply Risks Intensify
-
Lotte Merges with HD Hyundai: Can Korea’s Petrochemical First Case Trigger True Restructuring?
-
BASF and Evonik Rumored Potential Acquisition or Merger
Recommend Reading
-
![Ibuprofen API Giant to Expand Capacity by 50%, Annual Capacity to Reach 18,000 Tonnes]()
Ibuprofen API Giant to Expand Capacity by 50%, Annual Capacity to Reach 18,000 Tonnes
-
![AkzoNobel Rejects €12.5 Billion Offer from Nippon Paint and Sherwin-Williams, Sticks to Merger with Axalta]()
AkzoNobel Rejects €12.5 Billion Offer from Nippon Paint and Sherwin-Williams, Sticks to Merger with Axalta
-
![China Activates Blocking Rules in Response to U.S. Sanctions on Petrochemical Firms]()
China Activates Blocking Rules in Response to U.S. Sanctions on Petrochemical Firms
-
![Beiersdorf Launches Eucerin Skincare Brand in Japan]()
Beiersdorf Launches Eucerin Skincare Brand in Japan
-
![Korea’s Petrochemical Pivot: Industry Embraces Historic Restructuring to Slash Overcapacity]()
Korea’s Petrochemical Pivot: Industry Embraces Historic Restructuring to Slash Overcapacity
-
![Dichloromethane Stabilizes First, Then Collapses]()
Dichloromethane Stabilizes First, Then Collapses
-
![May Shandong Asphalt Market Ranges Within a Narrow Trading Band]()
May Shandong Asphalt Market Ranges Within a Narrow Trading Band
-
![China's Epichlorohydrin Market Supply and Demand Imbalance, Prices Falling]()
China's Epichlorohydrin Market Supply and Demand Imbalance, Prices Falling
-
![November Sodium Metabisulfite Price Increase]()
November Sodium Metabisulfite Price Increase
-
![Demand Flat, Adipic Acid Prices Decline in May]()
Demand Flat, Adipic Acid Prices Decline in May
